A Long-Term, Randomized, Double-Blind Study of the Safety, Tolerability and Efficacy of Aclidinum Bromide At Two Dosage Levels When Administered to Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease.

Trial Profile

A Long-Term, Randomized, Double-Blind Study of the Safety, Tolerability and Efficacy of Aclidinum Bromide At Two Dosage Levels When Administered to Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Aclidinium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 31 Jul 2013 Results published in Respiratory Medicine.
    • 05 Sep 2012 Tolerability results presented at the 22nd Annual Congress of the European Respiratory Society.
    • 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top